All In Biotech

Drug Trial Radar · NCT07821606

Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

An Open-label, Multicentre, Randomized, Controlled Phase III Clinical Trial Comparing HS-20089 Plus Bevacizumab Versus Investigator's Choice of Platinum-based Chemotherapy Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Dec 30, 2029

Study completion Dec 30, 2031

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III study evaluating the efficacy of HS-20089 in combination with bevacizumab versus investigator's choice of platinum-based chemotherapy in combination with bevacizumab in participants with platinum-sensitive recurrent ovarian cancer (PSOC).

Conditions

  • Platinum-sensitive Recurrent Ovarian Cancer

Interventions

  • HS-20089+BevacizumabDrug

    Experimental(Treatment group 1):HS-20089 in combination with Bevacizumab, administered according to the study protocol and as assessed by the investigator.

  • Dose 2:arboplatin+Paclitaxel+BevacizumabDrug

    Active Comparator(Treatment group2): Investigators selected treatment regimens based on participants' conditions(Paclitaxel or Doxorubicin Hydrochloride Liposome or Gemcitabine).All subjects will receive the investigator-selected drug in combination with Carboplatin and Bevacizumab, administered according to the study protocol and as assessed by the investigator.

  • Dose 3:arboplatin+Gemcitabine+BevacizumabDrug

    Active Comparator(Treatment group3): Investigators selected treatment regimens based on participants' conditions(Paclitaxel or Doxorubicin Hydrochloride Liposome or Gemcitabine).All subjects will receive the investigator-selected drug in combination with Carboplatin and Bevacizumab, administered according to the study protocol and as assessed by the investigator.

  • Dose 4:arboplatin+Doxorubicin Hydrochloride Liposome+BevacizumabDrug

    Active Comparator(Treatment group4): Investigators selected treatment regimens based on participants' conditions(Paclitaxel or Doxorubicin Hydrochloride Liposome or Gemcitabine).All subjects will receive the investigator-selected drug in combination with Carboplatin and Bevacizumab, administered according to the study protocol and as assessed by the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by BICRTime frame: Screening up to 3years

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Yuebei People's Hospital

    Shaoguan, Guangdong, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Jiangxi Maternal and Child Health Hospital

    Nanchang, Jiangxi, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Linyi People's Hospital

    Linyi, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • The Second Affiliated Hospital of Zhejiang University

    Hangzhou, Zhejiang, China

  • Zhejiang People's Hospital

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.